Home / Stocks / Lincoln Pharma Ltd
LINCOLN

Lincoln Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹512.05

Change

-2.4 (-0.47%)

Open

₹510.0

Prev. Close

₹514.45

Day High

₹515.45

Day Low

₹509.8

Volume Analysis

Traded

16,018

Delivered

8,677

Delivery %

54.17%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹520.71 ₹518.08 ₹515.06 ₹512.43 ₹509.41 ₹506.78 ₹503.76
Fibonacci ₹518.08 ₹515.92 ₹514.59 ₹512.43 ₹510.27 ₹508.94 ₹506.78
Camarilla ₹513.6 ₹513.09 ₹512.57 ₹512.43 ₹511.53 ₹511.01 ₹510.5

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+6.72%

1 Week

-1.17%

1 Month

-0.49%

3 Months

-16.61%

6 Months

-30.25%

1 Year

-4.0%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹632.34

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.19%

Net margin 13.43% × asset turnover 0.7x × equity multiplier 1.19x

Company Overview

Sector

Healthcare

Market Cap

₹1,032 Cr

P/E (TTM)

10.6

ROE

12.0%

Book Value

₹405.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Lincoln Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Momentum (22/100) is the weakest area to weigh before deciding. FII holding has been rising.

TopFund Score — Fundamentals Quality

59/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

41

Valuation

69

Cash Flow

67

Corporate Governance

63

Momentum

22

Institutional Ownership

43

Business Quality

67

Risk & Volatility

54

Liquidity

35

From Screener.in

  • +Company is almost debt free.
  • −The company has delivered a poor sales growth of 9.61% over past five years.
  • −Company has a low return on equity of 13.6% over last 3 years.
  • −Earnings include an other income of Rs.44.7 Cr.
  • −Dividend payout has been low at 4.11% of profits over last 3 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the …

Senior General Manager-Quality Assurance Pradeep Kumar Yadav resigned effective October 17, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 156 146 142 147 161 147 168 154 163 166 187 177 191
Expenses + 125 117 124 125 133 123 141 130 138 143 162 150 168
Operating Profit 31 30 18 23 28 24 27 24 25 24 25 27 24
OPM % 20.0% 20.0% 13.0% 15.0% 18.0% 16.0% 16.0% 15.0% 16.0% 14.0% 13.0% 15.0% 12.0%
Other Income + 9 11 7 10 10 9 -7 15 7 15 -4 24 10
Interest 0 0 0 0 0 1 0 0 0 0 0 0 0
Depreciation 3 3 3 3 3 3 3 3 4 4 4 4 4
Profit before tax 37 38 22 29 35 29 16 35 29 35 17 48 29
Tax % 25.0% 26.0% 16.0% 20.0% 24.0% 28.0% 29.0% 22.0% 31.0% 18.0% 30.0% 24.0% 30.0%
Net Profit + 28 28 19 24 26 21 12 28 20 29 12 36 20
EPS in Rs 14 14 9 12 13 10 6 14 10 14 6 18 10
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 9 27 9 3 0 18 5 1 13 11 15 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 266 400 360 361 366 386 424 472 510 581 623 671 722
Expenses + 240 359 313 308 299 321 337 376 421 480 522 573 623
Operating Profit 26 41 47 53 68 66 87 96 90 100 102 98 100
OPM % 10.0% 10.0% 13.0% 15.0% 18.0% 17.0% 21.0% 20.0% 18.0% 17.0% 16.0% 15.0% 14.0%
Other Income + 7 7 2 5 5 11 5 10 22 34 22 33 45
Interest 8 10 7 5 4 2 2 1 2 1 2 1 1
Depreciation 5 5 6 6 7 7 8 8 9 11 13 14 15
Profit before tax 20 33 37 46 62 67 84 96 100 122 109 116 128
Tax % 24.0% 28.0% 25.0% 25.0% 22.0% 23.0% 26.0% 28.0% 27.0% 24.0% 25.0% 24.0% —
Net Profit + 15 24 28 35 49 51 62 69 73 93 82 88 97
EPS in Rs 9 15 14 17 24 26 31 35 36 47 41 44 48
Dividend Payout % 11.0% 7.0% 9.0% 9.0% 6.0% 6.0% 5.0% 4.0% 4.0% 4.0% 4.0% 4.0% —
Sales growth 26 50 -10 0 2 6 10 11 8 14 7 8 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 95 124 172 204 249 293 346 413 482 573 652 738 792
Borrowings + 76 78 64 61 34 5 1 2 2 1 0 4 3
Other Liabilities + 70 56 48 62 63 71 85 99 83 106 125 128 149
Total Liabilities 258 275 305 347 366 389 452 534 587 700 797 890 964
Fixed Assets + 66 98 103 117 121 123 111 132 151 179 182 191 191
CWIP 3 3 7 0 2 0 2 16 7 3 4 5 7
Investments 0 0 10 11 18 34 81 97 91 139 174 209 245
Other Assets + 190 174 186 219 225 232 259 290 339 379 437 486 522
Total Assets 258 275 305 347 366 389 452 534 587 700 797 890 964
Equity Capital 16 16 20 20 20 20 20 20 20 20 20 20 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 25 45 25 27 53 75 69 76 39 63 93 106
Cash from Investing Activity + 7 -42 -25 -12 -18 -31 -64 -78 -37 -57 -79 -98
Cash from Financing Activity + -32 -3 0 -11 -36 -38 -6 -3 -4 -5 -6 0
Net Cash Flow -1 0 0 3 -1 7 -1 -4 -2 1 8 8
Free Cash Flow 21 11 7 17 38 68 61 31 26 24 74 82
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 109 126 74 68 104 137 102 104 77 89 117 135

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 49.81% → 49.78%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 46.92% 46.49% 46.24% 45.04% 45.07% 45.23% 45.08% 45.49% 45.51% 43.94% 45.36% 45.65%
Promoters 49.81% 49.54% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78%
FII 3.22% 3.93% 3.95% 5.19% 5.16% 5.0% 5.13% 4.73% 4.7% 5.2% 4.6% 4.55%
DII 0.06% 0.05% 0.04% 0.0% 0.0% 0.0% 0.01% 0.01% 0.01% 1.08% 0.27% 0.02%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Lincoln Pharma Ltd (this stock) 1,032 10.6 1.27 12.0%
Laxmi Dental Limited 1,076 29.7 4.05 14.8%
Sigachi Industries Ltd 1,088 41.3 2.02 5.78%
Bafna Pharmaceuticals Ltd 1,121 — 2.19 -6.18%
Themis Medicare Ltd. 929 624.0 2.33 0.41%
Gpt Healthcare Limited 1,136 27.3 — 28.5%
3b Blackbio Dx Ltd. 1,157 19.7 3.33 19.8%

Which Mutual Funds Hold Lincoln Pharma Ltd?

Frequently Asked Questions about Lincoln Pharma Ltd

Community Sentiment

What are other investors saying about Lincoln Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.